Parabilis Medicines, formerly known as FogPharma, has rebranded to emphasize its goal of making significant advancements in treating serious diseases and ensuring global access to its medicines. Unlike many companies that change their name to distance themselves from past issues, Parabilis is rebranding during a successful period, having recently won an industry award and secured substantial funding.
The new name, Parabilis, is inspired by Greek and Latin words meaning “beyond what’s possible” and “obtainable,” highlighting the company’s mission to push the boundaries of medicine and make treatments accessible. The CEO, Mathai Mammen, explained that the name reflects the team’s ambitious goals and focus on addressing unmet medical needs.
Despite the name change, the company continues to focus on its main drug candidate, FOG-001, which targets specific interactions in the body that could be effective against various mutations. Parabilis also introduced updates to its technology platform, which now uses AI and experimental methods to develop new peptide-based treatments for challenging targets.